EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische Studie (Phase II)Klinische Studie (Phase I)Open Access

Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm

Naveen Pemmaraju iD, Giovanni Marconi iD, Pau Montesinos iD, Andrew A Lane iD, Luca Mazzarella iD, David A Sallman iD, Matthew L Ulrickson iD, Gary J Schiller iD, Harry P Erba iD, Eunice S Wang iD, Roland B Walter iD, Eric Deconinck iD und 12 weitere

Journal of Clinical Oncology · 01.04.2026 · 44 (10) · 861-873

DOI: 10.1200/jco-25-02083 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 01.04.2026. Verfasst von Naveen Pemmaraju und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Immunological, Blastic Plasmacytoid Dendritic Cell Neoplasm. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a unique myeloid malignancy with CD123 interleukin-3 receptor-α overexpression and poor prognosis. METHODS This phase I/II, open-label, multicenter study evaluated pivekimab sunirine (PVEK), a novel CD123 antibody-drug conjugate, 0.045 mg/kg once every 3 weeks, in adults with frontline (no previous systemic therapy and de novo BPDCN or coexisting hematologic malignancy) or relapsed/refractory BPDCN (ClinicalTrials.gov identifier: NCT03386513 ) The primary end point in the primary analysis population (PAP; frontline de novo) was composite complete response (CCR; CR+ clinical CR) rate. RESULTS Of 84 patients, 33 had frontline BPDCN (22 de novo [20 in PAP]; 11 with previous or concomitant malignancy) and 51 had relapsed/refractory disease. The median (range) age was 72 (63-76) years. In the PAP (n = 20), the CCR rate was 75% (95% CI, 51 to 91; n = 15; median duration: 10.6 [95% CI, 3.8 to not reached] months) and the median overall survival (OS) was 16.6 (95% CI, 7.2 to not reached) months. Eight of these 15 (53%) patients proceeded to stem-cell transplant (SCT). The corresponding rate for relapsed/refractory disease was 14% (95% CI, 6 to 26; n = 7; median duration: 9.2 [95% CI, 2.4 to not reached] months), and the median OS was 5.8 (95% CI, 3.9 to 8.4) months. Adverse events (AEs) included peripheral edema (54%), fatigue (26%), and infusion-related reactions (26%). Grade ≥3 events included neutropenia (16%), thrombocytopenia (14%), and peripheral edema (12%). Serious AEs included pneumonia (6%) and febrile neutropenia (5%). Two on-treatment cases of reversible veno-occlusive disease (VOD) occurred. Of the total 19 patients who proceeded to SCT, VOD was reported in five patients (four with relapsed/refractory BPDCN). CONCLUSION PVEK, with convenient dosing, led to high, durable responses, especially in frontline BPDCN, and a manageable safety profile.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalBlastic Plasmacytoid Dendritic Cell NeoplasmAgedFemaleHumansMaleMiddle Aged

Substanzen

Antibodies, Monoclonal, HumanizedAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • University of Bologna, Hematology Unit, Ospedale S. Maria delle Croci, Ravenna (RA), Italy.
  • Department of Hematology, Hospital Universitari i Politècnic La Fe, Valencia, Spain.
  • Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • Early Drug Development for Innovative Therapies Division, IRCCS IEO-Istituto Europeo di Oncologia, Milan, Italy.
  • Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL.

ORCID-Profile: Naveen Pemmaraju, Giovanni Marconi, Pau Montesinos, Andrew A Lane, Luca Mazzarella, David A Sallman, Matthew L Ulrickson, Gary J Schiller, Harry P Erba, Eunice S Wang, Roland B Walter, Eric Deconinck, Delphine Lebon, Daniel J DeAngelo, Enrico Derenzini, Hagop M Kantarjian, Naval G Daver

Förderung

  • NCI NIH HHS

Zitieren

APA

Pemmaraju, N., Marconi, G., Montesinos, P., Lane, A. A., Mazzarella, L., Sallman, D. A., Ulrickson, M. L., Schiller, G. J., Erba, H. P., Wang, E. S., Walter, R. B., Deconinck, E., Aribi, A., Legrand, O., Lebon, D., Maisano, V., Martinelli, G., DeAngelo, D. J., Derenzini, E., …, & Daver, N. G. (2026). Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm. Journal of Clinical Oncology, 44(10), 861-873. https://doi.org/10.1200/jco-25-02083

Vancouver

Pemmaraju N, Marconi G, Montesinos P, Lane AA, Mazzarella L, Sallman DA, et al. Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm. Journal of Clinical Oncology. 2026;44(10):861-873. doi:10.1200/jco-25-02083

BibTeX
@article{Pemmaraju2026,
  author = {Pemmaraju, Naveen and Marconi, Giovanni and Montesinos, Pau and Lane, Andrew A and Mazzarella, Luca and Sallman, David A and Ulrickson, Matthew L and Schiller, Gary J and Erba, Harry P and Wang, Eunice S and Walter, Roland B and Deconinck, Eric and Aribi, Ahmed and Legrand, Ollivier and Lebon, Delphine and Maisano, Valerio and Martinelli, Giovanni and DeAngelo, Daniel J and Derenzini, Enrico and Du, Yining and Lakshmikanthan, Sribalaji and Potluri, Jalaja and Kantarjian, Hagop M and Daver, Naval G},
  title = {Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  volume = {44},
  number = {10},
  pages = {861--873},
  doi = {10.1200/jco-25-02083}
}
Kostenlos starten →